Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer
From Molecular Insights to Precision Solutions
- 1st Edition, Volume 21 - January 23, 2024
- Imprint: Academic Press
- Editor: Zodwa Dlamini
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 8 9 8 5 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 9 8 6 - 6
Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions, Volume 21 highlights different strategies to reverse chemot… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteStrategies for Overcoming Chemotherapy Resistance in Cervical Cancer: From Molecular Insights to Precision Solutions, Volume 21 highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book puts a strong focus on strategies to reverse chemotherapy resistance as well as strategies for early detection of the resistance, enhancing precision oncology in terms of patient care and maximizing patient management. The book also looks at virally induced resistance to chemotherapy and recommends combination therapies that can maximize the reversal of this resistance.
In 10 chapters, the book not only gives an overview of cervical cancer and chemotherapy as treatment, but also investigates resistance to chemotherapy and treatment for resistance. It defines treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence.
In 10 chapters, the book not only gives an overview of cervical cancer and chemotherapy as treatment, but also investigates resistance to chemotherapy and treatment for resistance. It defines treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence.
- Discusses strategies to reverse and detect resistance to chemotherapy at an early stage
- Investigates the applications of Artificial Intelligence in the study of cervical chemotherapy resistance
- Presents research and applications developed to overcome cancer resistance
Researchers working across the biosciences in fields of oncology, virology and artificial intelligence
- Cover image
- Title page
- Table of Contents
- Copyright
- Cover Image Legend
- Aims and Scope for Series “Cancer Sensitizing Agents for Chemotherapy”
- About the Series Editor
- Aims and Scope of the Volume
- About the Volume Editor
- Preface
- Contributors
- Chapter 1 An overview of cervical cancer, chemotherapy as treatment and chemotherapy resistance
- Abstract
- Conflict of interest
- Introduction
- Staging for cervical cancer
- The role of chemotherapy in the treatment of cervical cancer
- Mode of action: Cisplatinum
- The role of immunotherapy in the treatment of cervical cancer
- Understanding the pathway for chemotherapy resistance
- Classification of cisplatin resistance
- Overcoming chemotherapy resistance for future management of cervical cancer
- Challenges for overcoming chemotherapy resistance in cervical cancer
- Conclusion
- References
- Chapter 2 Current treatment options and limitations for cervical cancer
- Abstract
- Conflict of interest
- Introduction—Current approach to cervical cancer therapies
- Chemotherapy regimens and their effectiveness
- Targeted therapies and immunotherapies
- Combination therapies and clinical trials
- Limitations of current treatment options
- Conclusions
- References
- Chapter 3 Radiotherapy treatment resistance in cervical cancer
- Abstract
- Conflict of interest
- Introduction
- Conventional clinical-pathological factors
- Genomic markers of lymph node metastases
- Pathological tumor type and treatment resistance
- Genetic alterations associated with treatment response
- Limitations
- Conclusion
- References
- Chapter 4 Mechanisms of chemotherapy resistance in cervical cancer
- Abstract
- Conflict of interest
- Background
- The tumor microenvironment (TME) as an enabling environment in CC chemoresistance
- Signaling pathways and epigenetics in CC chemoresistance
- Metabolic alterations in chemoresistance
- Combinatorial therapies in overcoming CC
- Limitations and challenges of targeting cellular and molecular mechanisms in CC chemoresistance
- Conclusions
- References
- Chapter 5 Reversal of resistance mechanisms in cervical cancer
- Abstract
- Conflict of interest
- Introduction
- Identification of resistance mechanisms
- Development of novel drugs and methods to target resistance mechanisms
- Repurposing of existing drugs
- Combination therapies to overcome resistance
- Conclusion
- References
- Chapter 6 HPV- and HIV-associated epigenetic silencing in cervical cancer: Targets for overcoming chemoresistance
- Abstract
- Conflict of interest
- Introduction
- HPV, HIV, and cervical cancer
- DNA methylation and chemoresistance in cervical cancer
- Histone acetylation
- Potential epigenetic biomarkers for cervical cancer treatment
- Challenges and limitations of epigenetic biomarkers for cervical cancer treatment
- Conclusion and future perspective
- References
- Chapter 7 Splicing-associated chemotherapy resistance in cervical cancer: Targeting splicing signatures
- Abstract
- Conflict of interest
- Introduction
- Alternative splicing as a normal biological process
- Dysregulated alternative splicing in cervical neoplasia and alterations in splicing regulatory factors
- Splicing and chemoresistance in CC
- CeRNA networks promote chemoresistance through alternative splicing regulation
- Limitations and challenges of targeting splicing signatures in alleviating CC chemoresistance
- Conclusion
- References
- Chapter 8 MicroRNA involvement in cervical cancer chemotherapy drug resistance: Restoring sensitivity to chemotherapeutic drugs
- Abstract
- Conflict of interest
- Introduction
- MicroRNAs—The potential cervical cancer treatment
- Challenges and limitations
- Conclusion
- References
- Chapter 9 Future directions in cervical cancer treatment
- Abstract
- Conflict of interest
- Introduction
- The roadmap to elimination of cervical cancer by 2030
- Personalized medicine and precision oncology
- Indigenous knowledge systems
- Identification of biomarkers for resistance
- Challenges and limitations
- Conclusion
- References
- Chapter 10 Conclusion: Overcoming chemoresistance in cervical cancer
- Abstract
- Conflict of interest
- Index
- Edition: 1
- Volume: 21
- Published: January 23, 2024
- No. of pages (Hardback): 216
- No. of pages (eBook): 200
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443289859
- eBook ISBN: 9780443289866
ZD
Zodwa Dlamini
Zodwa Dlamini is a Professor of Molecular Oncology and the founding Director and the Executive Head of the Pan African Cancer Research Institute (PACRI) in South Africa. She is the Director of South African Medical Research Council (SAMRC) Precision Oncology Research Unit (PORU). She is the DSI/NRF SARChI Chair in Precision Oncology and Cancer Prevention (POCP). She is a member of the American Association for Cancer Research (AACR) Advisory Group on Sub-Saharan Africa. She is a member of the AACR Pathology Resources in Africa Advisory Group. Professor Dlamini is a member of the African Organisation for Research and Training in Cancer (AORTIC) Research Committee Scientific Advisory Board. She is an elected member of the Academy of Science of South Africa. Professor Dlamini is an overseas Fellow of the Royal Society of Medicine (London). She is the Associate Editor for Frontiers in Oncology: Cancer Genetics Section
Affiliations and expertise
University of Pretoria, South AfricaRead Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer on ScienceDirect